Strategic Acquisition Adverum Biotechnologies recently attracted acquisition interest from Eli Lilly, signaling a potential buyer-led engagement channel. Sales teams should position complementary gene therapy partnerships and licensing discussions, highlighting Ixo-vec as a leading IVT single-administration platform for ocular diseases.

Expanded Investor Activity With Lilly’s planned acquisition and ongoing clinical programs, there is increased market visibility and funding momentum. Business development can leverage this to secure co-development or equity-for-technology deals, targeting partnerships that accelerate manufacturing, CMC assay development, and regulatory strategy.

Orphan/Ocular Market The focus on highly prevalent ocular diseases and the aim to become a standard of care for retinal conditions creates a sizeable addressable market. Sales strategies should target ophthalmology networks, payer value proposition, and physician office delivery workflows for one-time gene therapies.

CMC and Assay Leadership Recent recognition in light scattering assays and strong CMC capabilities present opportunities to offer collaboration on analytics, characterization services, and quality control for AAV-based products. Consider proposing CRO/CMO partnerships or joint-development of robust assay pipelines.

Global Deployment Readiness One-time IVT injections compatible with physician office delivery imply a scalable, clinic-friendly model. BD discussions can emphasize manufacturing scalability, supply chain readiness, and training programs to enable widespread adoption in ophthalmology clinics post-approval.